# Dimitrios Patoulias

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/dimitrios-patoulias/

## Facts

| Field | Value |
| --- | --- |
| Citations | 23,474 |
| Field | Diabetes Treatment and Management |
| h-index | 37 |
| i10-index | 112 |
| Last Known Institution | Aristotle University of Thessaloniki |
| OpenAlex ID | https://openalex.org/A5055456426 |
| ORCID iD | 0000-0002-6899-684X |
| Works | 427 |

## Researcher papers

- [Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis](https://scholariq.org/papers/effect-of-glucagon-like-peptide-1-receptor-agonists-and-co-agonists-on-body/)
- [Triglyceride-glucose index (TyG) as a novel biomarker in the era of cardiometabolic medicine](https://scholariq.org/papers/triglyceride-glucose-index-tyg-as-a-novel-biomarker-in-the-era-of/)
- [Prognostic value of stress hyperglycemia ratio in patients with acute myocardial infarction: A systematic review with Bayesian and frequentist meta-analysis](https://scholariq.org/papers/prognostic-value-of-stress-hyperglycemia-ratio-in-patients-with-acute-myocardial/)
- [Atrial Fibrosis in Atrial Fibrillation: Mechanistic Insights, Diagnostic Challenges, and Emerging Therapeutic Targets](https://scholariq.org/papers/atrial-fibrosis-in-atrial-fibrillation-mechanistic-insights-diagnostic/)
- [Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials](https://scholariq.org/papers/safety-and-efficacy-of-the-new-oral-small-molecule-glp-1-receptor-agonists/)
- [Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta‐analysis](https://scholariq.org/papers/effect-of-tirzepatide-on-albuminuria-levels-and-renal-function-in-patients-with/)
- [Therapeutic Potential of Sodium-glucose Co-transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists for Patients with Acute Coronary Syndrome: A Review of Clinical Evidence](https://scholariq.org/papers/therapeutic-potential-of-sodium-glucose-co-transporter-2-inhibitors-and-glucagon/)
- [Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors combination therapy versus monotherapy and major adverse cardiovascular events: Do the benefits add up?](https://scholariq.org/papers/glucagon-like-peptide-1-receptor-agonists-and-sodium-glucose-cotransporter-2/)
- [Intracoronary Thrombolysis in ST-Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: an Updated Meta-analysis of Randomized Controlled Trials](https://scholariq.org/papers/intracoronary-thrombolysis-in-st-segment-elevation-myocardial-infarction/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Potassium and Related Disorders](https://scholariq.org/topics/potassium-and-related-disorders/)

## Researcher university

- [Aristotle University of Thessaloniki](https://scholariq.org/institutions/aristotle-university-of-thessaloniki/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.